Sign in to view content

Pharmacokinetic Profile of the Port Delivery System With Ranibizumab: From PRN Refills in Phase 2 Ladder to Fixed 24-Week Refills In Phase 3 Archway

Dilsher S. Dhoot, MD

Video
Published 2020

Related

New Biosimilar Bevacizumab and Ranibizumab for Retinal Diseases
Alay S. Banker, MD
Annual Meeting Talks
2018
Faricimab Causes Rapid and Sustained Intraocular Suppression of Ang-2 and VEGF-A for Up to 16 Weeks in nAMD and DME
Rajeev H. Muni, MD, MSC, FRCS(C), FASRS
Annual Meeting Talks
2023
Gene Expression Modifications in Anti-VEGF Treated Retinal Müller Cells
Baruch D. Kuppermann, MD, PhD
Annual Meeting Talks
2016

Category: AMD-Neovascular

See more